Host determinants of antiretroviral drug activity

Current Opinion in Infectious Diseases

Volumn 18, Issue 6, 2005, Pages 543-549

  Boffito, Marta ^a   Winston, Alan ^a   Owen, Andrew ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antitretroviral drugs; HIV infection; Pharmacogenetics

Indexed keywords

ABACAVIR; ABC TRANSPORTER; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5; EFAVIRENZ; ENFUVIRTIDE; GLYCOPROTEIN P; INDINAVIR; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; THYMIDINE KINASE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; ENZYME ACTIVITY; ETHNOLOGY; FEVER; GASTROINTESTINAL SYMPTOM; GENETIC VARIABILITY; GENOTYPE; GLUCURONIDATION; HEALTH CARE PLANNING; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; IMMUNE RESPONSE; INJECTION SITE REACTION; INSULIN RESISTANCE; LIPID STORAGE; LIPOATROPHY; MACROPHAGE; PHARMACOGENETICS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; VIRUS REPLICATION;

EID: 27744482950     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000191507.48481.10     Document Type: Review

References (84)

1. Pozniak A, Gazzard B, Anderson J, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003; 4 (Suppl 1):1-41.
2. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. Aids 2002; 16 (Suppl 1): S5-S37.
3. Hoehe MR, Timmermann B, Lehrach H. Human inter-individual DNA sequence variation in candidate genes, drug targets, the importance of haplotypes and pharmacogenomics. Curr Pharm Biotechnol 2003; 4:351-378.
4. Sebat J, Lakshmi B, Troge J, et al. Large-scale copy number polymorphism in the human genome. Science 2004; 305:525-528.
5. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003; 138:620-626.
6. Boffito M, Acosta E, Burger D, et al. Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antivir Ther 2005; 10:375-392.
7. Fletcher CV, Kawle SP, Kakuda TN, et al. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. Aids 2000; 14:2137-2144.
8. Turriziani O, Scagnolari C, Bellomi F, et al. Cellular issues relating to the resistance of HIV to antiretroviral agents. Scand J Infect Dis Suppl 2003; 35 (Suppl 106):45-48.
9. Antonelli G, Turriziani O, Verri A, et al. Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase. AIDS Res Hum Retroviruses 1996; 12:223-228.
10. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996; 6:610-617.
11. Fridland A, Connelly MC, Robbins BL. Cellular factors for resistance against antiretroviral agents. Antivir Ther 2000; 5:181-185.
12. Schuetz JD, Connelly MC, Sun D, et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999; 5:1048-1051.
13. Turriziani O, Schuetz JD, Focher F, et al. Impaired 2′,3′- dideoxy-3′-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11. Biochem J 2002; 368:325-332.
14. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23:1603-1614.
15. Symonds W, Cutrell A, Edwards M, et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther 2002; 24:565-573.
16. Peyrieere H, Nicolas J, Siffert M, et al. Hypersensitivity related to abacavir in two members of a family. Ann Pharmacother 2001; 35:1291-1292.
17. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-732.
18. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359:1121-1122.
19. Hughes DA, Vilar FJ, Ward CC, et al. Cost-effectiveness analysis of HLA-B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14:335-342.
20. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A 2004; 101:4180-4185.
21. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5:203-211.
22. Winston A, Boffito M. The management of HIV-1 protease inhibitor pharmacokinetic interactions. J Antimicrob Chemother 2005; 56:1-5.
23. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5:54-59.
24. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66:15-27.
25. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-391.
26. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20:342-349.
27. RebbeckTR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90:1225-1229.
28. von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A through concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47:1048-1052.
29. Lee SJ, Bell DA, Coulter SJ, et al. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther 2005; 313:302-309.
30. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11:399-415.
31. Lang T, Klein K, Richter T, et al. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 2004; 311:34-43.
32. Gazzard BG. Efavirenz in the management of HIV infection. Int J Clin Pract 1999; 53:60-64.
33. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids 2004; 18:2391-2400. Novel data to improve the management of HIV patients on antiretroviral agents.
34. Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 2004; 319:1322-1326.
35. Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005; 40:1358-1361.
36. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15:1-5.
37. Owen A, Almond L, Hartkoorn R, et al. Relevance of drug transporters and drug metabolism enzymes to nevirapine: superimposition of host genotype. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA; February 2005. Abstract 650.
38. Haas DW, Bartlett J, Andersen J, et al. Pharmacogenetics of nevirapine and hepatotoxicity: NWCS220, an ACTG Collaborative Study. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA; February 2005. Abstract 833.
39. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005; 44:33-60.
40. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther 2004; 76:467-479.
41. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003; 42:107-121.
42. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004; 44:499-523.
43. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. Aids 2003; 17:2159-2168.
44. Burger D, la Porte CGL, van der Ende ME, et al. Gender-related differences in efavirenz pharmacokinetics. 4th International Workshop on Clinical Pharma-cology of HIV Therapy, Cannes; 2003. Abstract 3.6.
45. la Porte CGL, Burger D, Gyssens L, et al. Gender differences in nevirapine pharmacokinetics, fact or fiction? 4th International Workshop on Clinical Pharmacology of HIV Therapy, Cannes; 2003. Abstract 3.1.
46. Gatti G, de Pascalis CR, de Luca A, et al. Predictors of amprenavir parameters of drug exposure in heavily pretreated HIV+ patients. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, UK; 2002. Abstract P165.
47. Burger DM, Siebers MC, Hugen PW, et al. Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? J Acquir Immune Defic Syndr 2002; 29:101-102.
48. Pai MP, Schriever CA, Diaz-Linares M, et al. Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. Pharmacotherapy 2004; 24:592-599.
49. Ribera E, Lopez RM, Diaz M, et al. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2004; 48:4256-4262.
50. Fletcher CV, Jiang H, Brundage RC, et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis 2004; 189:1176-1184.
51. Cardiello PG, van Heeswijk RP, Hassink EA, et al. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. J Acquir Immune Defic Syndr 2002; 29:464-470.
52. Becker S, Tse M, Sterman F, et al. Pharmacokinetics of once-daily saquinavir hard-gel capsule with low-dose ritonavir or full-dose atazanavir in seronegative volunteers: ASPIRE I. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA; 2005. Abstract 655.
53. Dickinson L, Back D, Chandler B, et al. The impact of gender on saquinavir hard gel/ritonavir (1000/100 mg bid) pharmacokinetics and PBMC transporter expression in HIV-1 infected individuals. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, Canada; April 2005. Abstract 9.
54. Hoggard PG, Owen A. The mechanisms that control intracellular penetration of the HIV protease inhibitors. J Antimicrob Chemother 2003; 51:493-496.
55. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30-36.
56. Owen A, Chandler B, Back DJ. The implications of P-glycoprotein in HIV: friend or foe? Fundam Clin Pharmacol 2005; 19:283-296.
57. Hitzl M, Drescher S, van der Kuip H, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 1 23 from CD56+ natural killer cells. Pharmacogenetics 2001; 11:293-298.
58. Owen A, Chandler B, Bray PG, et al. Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J Virol 2004; 78:12022-12029. Novel and interesting scientific data to clarify the complex role of transporters in HIV infection.
59. Boffito M, Back DJ, Blaschke TF, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003; 19:825-835.
60. Kremer JM, Wilting J, Janssen LH. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988; 40:1-47.
61. Oie S, Jacobson MA, Abrams DI. Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV). J Acquir Immune Defic Syndr 1993; 6:531-533.
62. Herve F, Caron G, Duche JC, et al. Ligand specificity of the genetic variants of human alpha1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant. Mol Pharmacol 1998; 54:129-138.
63. Owczarek CM, Owczarek AL, Board PG. Identification and characterization of polymorphisms at the HAS alpha1-acid glycoprotein (ORM*) gene locus in Caucasians. Genet Mol Res 2002; 1:96-105.
64. Rodrigues-Lima F, Dupret JM. Regulation of the activity of the human drug metabolizing enzyme arylamine N-acetyltransferase 1: role of genetic and non genetic factors. Curr Pharm Des 2004; 10:2519-2524.
65. Mackenzie PI, Miners JO, McKinnon RA. Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clin Chem Lab Med 2000; 38:889-892.
66. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 2005; 49:1733-1738.
67. Atazanavir (package insert). Princeton, NJ: Bristol-Myers Squibb.
68. Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 2004; 24:1732-1747.
69. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 2003; 3:136-158.
70. Haas DW, Pharmacogenomics. HIV therapeutics. J Infect Dis 2005; 191:1397-1400.
71. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1:507-537.
72. Li WW, Dammerman MM, Smith JD, et al. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995; 96:2601-2605.
73. Dammerman M, Sandkuijl LA, Halaas JL, et al. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci U S A 1993; 90:4562-4566.
74. Tarr PE, Taffe P, Bleiber G, et al. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 2005; 191:1419-1426. Clear and interesting study clarifying the importance of pharmacogenetics in relation to the development of antiretroviral-related metabolic adverse events.
75. Fauvel J, Bonnet E, Ruidavets JB, et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. Aids 2001; 15:2397-2406.
76. Maher B, Alfirevic A, Vilar FJ, et al. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. Aids 2002; 16:2013-2018.
77. Nolan D, Moore C, Castley A, et al. Tumour necrosis factor-alpha gene - 238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. Aids 2003; 17:121-123.
78. Bonora S, Gonzalez de Requena D, Castagna A, et al. Pharmacokinetic and pharmacodynamic determinants of virological response to enfuvirtide-based regimens. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 2005. Poster 643.
79. Peytavin G, Ronault A, Marcelin AG, et al. Plasma concentrations of enfuvirtide (ENF) in highly experienced HIV-infected patients. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, Canada; April 2005. Poster 57.
80. Cooper DA, Group TAI. An analysis of the correlation between the severity of injection site reactions and the amount of subcutaneous fat in the alliance cohort. 12th Conference of Retroviruses and Opportunistic Infections, Boston, MA; February 2005. Poster 838.
81. Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726-735.
82. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955-1958.
83. Sheppard HW, Celum C, Michael NL, et al. HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype. J Acquir Immune Defic Syndr 2002; 29:307-313.
84. Princen K, Schols D. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokine Growth Factor Rev 2005; 5 July [Epub ahead of print]. Comprehensive review on novel anti-HIV agents.